Verein für
Association pour le
Associazione per il

medizinische Qualitätskontrolle
contrôle de qualité médical
controllo di qualità medico

Survey Report

2022 - 4

MQ, Institut für Klinische Chemie, Universitätsspital Zürich, 8091 Zürich
Telefon 044/255 34 11, www.MQZH.ch, info@MQZH.ch

Survey Specimens
The homogeneity and stability of all specimens were checked before and/or during shipment and no irregularities were noted. The suitability tests were performed by the laboratories of the Universitätsspital Zürich (University Hospital Zurich) (http://www.uzl.usz.ch/).
The following survey specimens were produced specifically for MQ by a sub-contractor:
B1 Strep A Test, B2 Uricult, H4 Parasitic Hematology, K14 tumor marker

Determination of target values

For each target value, the type of determination per ISO17043: 2010 B2.1 is indicated (column "type"):
a Value known due to production.
b Certified reference value for use with special specimens
c Reference value determined by analysis
d Consensus values of expert laboratories
e Consensus values of the participants

For methods groups with more than 9 participants, consensus values of the participants ("e") are generally determined.
In order to calculate the target values, we use the mean value of the method group. Values that differ more than 1.5 times the QUALAB-tolerance are outliers and are not used to calculate the target value. Starting point for the elimination of outliers are the values of our suitability tests.
In order to provide all participants with target values that are as meaningful as possible, other methods may also be applied for smaller method groups.

Uncertainty of the determined target values
The standard uncertainty (u_x) is calculated using the following formula (ISO13528):
ux = (target value/100) * (1.25/square root of "number of participants") * %CV

- ux has the same unit as the target value
- ux can be compared with the standard deviation of the participants' collective (SD=target value*%CV/100)
- For participant numbers >18, the standard uncertainty (ux) is significantly lower than the scatter of the collective participants and can be neglected.

QUALAB and MQ tolerances

For all mandatory analyzes, QUALAB tolerances are used (www.qualab.ch, external quality control). For non-mandatory analyzes, the tolerances are specified by MQ's survey specimen leader.

If the determined uncertainty, ux, of the target value is greater than 15% of the QUALAB or MQ tolerance, the letter indicating the type of target detection is marked with an additional star (example "e*"). Thereby, we are alerting the participants to the fact that the uncertainty of the target value can have an impact on the evaluation.

Graphics
The results are shown graphically as follows:



Comparison of Devices
The data in this report allows you to compare the performance of different devices. However, remember to consider the following:

- The chemical control K1 is a ready-to-use commercial control serum. Even if the specimen is of human origin, it is possible that matrix effects occur. These are device-specific and result in different target values.
- Only one specimen was measured. Since the scatter of the results is dependent on the nature of the specimen (matrix effects) and on the signal strength, the determined coefficient of variations (CV in %) cannot be applied generally.
- A large number of runaways is due to administrative errors (wrong unit, results mixed up) or to operator errors (wrong sample, not correctly taken up in solution, not mixed well) and has nothing to do with the type of device.

.

Zürich, 12.12.2022

Dr. R. Fried
Survey Director

Publication of this report or any portion thereof without our prior written consent is not permitted. The original is archived at www.mqzh.ch

.

INR



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	15	100.0	0.0	0.0	1.56	4.0	e
2	Neoplastin R	12	100.0	0.0	0.0	1.73	3.6	e
3	Neoplastin Plus	5	100.0	0.0	0.0	2.04	3.8	e
4	Recombiplastin 2G	12	100.0	0.0	0.0	1.70	5.6	e
5	Other methods	16	100.0	0.0	0.0	1.65	6.8	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Fibrinogen OA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	9	100.0	0.0	0.0	1.06	5.2	e
2	Stago/STA	16	100.0	0.0	0.0	1.13	4.8	e
3	Fibrinogen Q.F.A.	6	100.0	0.0	0.0	1.18	8.2	e*
4	Other methods	5	100.0	0.0	0.0	1.13	4.0	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Activated Prothrombin Time



QUALAB tolerance : 25 %

Activated Prothrombin Time (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	8	100.0	0.0	0.0	41.4	6.9	e
2	Pathromtin SL	4	100.0	0.0	0.0	65.7	0.6	e
3	Stago/STA	15	100.0	0.0	0.0	50.6	4.9	e
4	aPTT-SP	7	100.0	0.0	0.0	42.0	7.2	e
5	Other methods	11	100.0	0.0	0.0	42.5	10.6	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

INR CoaguChek



QUALAB tolerance : 15 %

INR CoaguChek ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	761	98.7	0.4	0.9	3.2	3.5	e

Prothrombin time NT



QUALAB tolerance : 15 %

Prothrombin time NT (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	11	90.9	0.0	9.1	98	1.6	e
2	Neoplastin R	12	100.0	0.0	0.0	95	4.5	e
3	Neoplastin Plus	6	100.0	0.0	0.0	93	5.5	e*
4	Recombiplastin 2G	8	100.0	0.0	0.0	100	2.9	e
5	Other methods	14	100.0	0.0	0.0	99	4.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Faktor II



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	94.4	6.5	e*

Fibrinogen N



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	7	100.0	0.0	0.0	2.70	3.1	e
2	Stago/STA	16	100.0	0.0	0.0	3.02	5.5	e
3	Fibrinogen Q.F.A.	7	100.0	0.0	0.0	2.80	5.7	e*
4	Fib Clauss (IL)	5	100.0	0.0	0.0	3.12	5.7	e*
5	Other methods	8	100.0	0.0	0.0	2.82	6.2	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Faktor V



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	92.2	13.5	e*

aPTT N



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	9	100.0	0.0	0.0	22.7	4.9	e
2	Stago/STA	19	100.0	0.0	0.0	31.2	4.3	e
3	aPTT-SP	10	90.0	0.0	10.0	25.8	5.8	e
4	Other methods	11	100.0	0.0	0.0	30.9	16.1	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Faktor VII



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	5	100.0	0.0	0.0	99.0	3.3	e

Prothrombin time HT



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Innovin	12	100.0	0.0	0.0	83	4.7	e
2	Neoplastin R	10	100.0	0.0	0.0	92	3.8	e
3	Recombiplastin 2G	11	100.0	0.0	0.0	92	3.0	e
4	Other methods	8	100.0	0.0	0.0	88	5.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (unfrakt-Heparin)



MQ tolerance : 20 %

Anti-FXa (unfrakt-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	7	85.7	14.3	0.0	0.22	11.9	e*
2	ACL	18	100.0	0.0	0.0	0.41	12.9	a
3	Other methods	11	100.0	0.0	0.0	0.45	12.8	e*

Fibrinogen H



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens Thrombin	4	100.0	0.0	0.0	2.86	3.0	e
2	Stago/STA	13	100.0	0.0	0.0	2.94	4.2	e
3	Fibrinogen Q.F.A.	13	92.3	0.0	7.7	2.93	5.5	e
4	Other methods	8	100.0	0.0	0.0	2.85	5.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

aPTT H



QUALAB tolerance : 25 %

aPTT H (Sek)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Actin FS	4	100.0	0.0	0.0	39.8	5.5	e
2	Actin FSL	4	100.0	0.0	0.0	42.5	1.4	e
3	Stago/STA	11	100.0	0.0	0.0	57.7	5.7	e
4	aPTT-SP	13	92.3	0.0	7.7	69.8	9.1	e
5	Other methods	6	100.0	0.0	0.0	45.2	9.3	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

D-dimer



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas (Heparinplasma	4	100.0	0.0	0.0	3.54	11.4	e*
2	STA Liatest	15	100.0	0.0	0.0	3.20	4.7	e
3	Siemens Innovance	13	100.0	0.0	0.0	5.46	9.0	e
4	Pathfast	8	100.0	0.0	0.0	5.00	0.0	e
5	Eurolyser	4	100.0	0.0	0.0	6.45	5.8	e*
6	ACL	9	100.0	0.0	0.0	5.50	6.6	e
7	AQT 90 FLEX	8	100.0	0.0	0.0	2.49	3.0	e
8	VIDAS	15	100.0	0.0	0.0	3.21	4.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

CoaguChek APTT



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek Pro II	4	100.0	0.0	0.0	90.8	7.8	e*

INR CCXS



QUALAB tolerance : 15 %

INR CCXS ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CoaguChek XS	1550	98.4	0.4	1.2	2.0	3.4	e

INR HC



QUALAB tolerance : 15 %

INR HC ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemochron j.	8	100.0	0.0	0.0	4.9	2.5	e

INR MI



QUALAB tolerance : 15 %

INR MI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MicroINR	128	80.4	6.3	13.3	2.5	8.5	e

INR Xprecia



QUALAB tolerance : 15 %

INR Xprecia ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Xprecia	56	98.2	0.0	1.8	2.6	3.6	e

INR Lumira Dx



QUALAB tolerance : 15 %

INR Lumira Dx ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	9	77.8	22.2	0.0	4.8	11.2	e*

Anti-FXa (LMW-Heparin)



MQ tolerance : 20 %

Anti-FXa (LMW-Heparin) (IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	8	100.0	0.0	0.0	0.59	3.5	e
2	ACL	13	100.0	0.0	0.0	0.67	12.0	e*
3	Other methods	16	93.7	6.3	0.0	0.80	8.7	e

Anti-FXa (Rivaroxaban)



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Stago/STA	13	100.0	0.0	0.0	309.31	3.3	e
2	ACL	7	100.0	0.0	0.0	277.30	8.2	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (Apixaban)

MQ tolerance : 20 %

Anti-FXa (Apixaban) (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ACL	4	100.0	0.0	0.0	295.60	7.0	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-FXa (Edoxaban)



No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	135.45	5.9	e*

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	16	100.0	0.0	0.0	108.4	2.9	e
2	Cyanmethemoglobin	18	94.4	0.0	5.6	109.0	2.6	e
3	Sysmex X	48	97.9	2.1	0.0	109.2	2.6	e
4	Hemocue	407	96.5	1.5	2.0	109.0	2.3	e
5	Hemocontrol	9	100.0	0.0	0.0	111.0	3.7	e*
6	DiaSpect	14	85.7	0.0	14.3	117.4	4.0	e
7	Sysmex	9	100.0	0.0	0.0	109.0	1.0	e
8	Other methods	4	0.0	0.0	100.0	84.5	0.0	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex KX21	141	99.3	0.0	0.7	109.2	1.8	e
2	Sysmex PocH - 100i	199	97.0	1.0	2.0	107.5	2.4	e
3	Sysmex XP 300	623	97.9	0.0	2.1	108.6	1.5	e
4	Mythic	250	96.0	0.8	3.2	107.3	2.8	e
5	Sysmex XQ-320	43	97.7	0.0	2.3	110.2	1.1	e
6	Swelab	30	100.0	0.0	0.0	112.7	3.2	e
7	Abacus Junior	4	100.0	0.0	0.0	108.5	5.1	e*
8	Medonic	4	100.0	0.0	0.0	112.5	1.1	e
9	Celltac Alpha (Nihon	87	94.3	1.1	4.6	110.3	2.2	e
10	Samsung HC10	18	100.0	0.0	0.0	109.2	3.3	e
11	Micros 60	85	96.5	3.5	0.0	107.6	3.4	e

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	15	93.3	6.7	0.0	0.30	6.0	e*
2	Sysmex X	48	100.0	0.0	0.0	0.31	2.2	e
3	Sysmex	9	100.0	0.0	0.0	0.31	3.1	e

11 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	43	97.7	0.0	2.3	0.30	1.9	e
2	Sysmex KX21	140	99.3	0.0	0.7	0.29	2.5	e
3	Sysmex PocH - 100i	199	97.0	0.5	2.5	0.32	2.7	e
4	Sysmex XP 300	623	97.8	0.8	1.4	0.29	2.2	e
5	Mythic	252	91.2	3.2	5.6	0.30	3.6	e
6	Swelab	30	100.0	0.0	0.0	0.31	3.5	e
7	Abacus Junior	4	75.0	25.0	0.0	0.33	4.9	e*
8	Medonic	4	100.0	0.0	0.0	0.31	2.5	e*
9	Celltac Alpha (Nihon	86	89.5	3.5	7.0	0.31	3.1	e
10	Samsung HC10	18	94.4	5.6	0.0	0.31	4.4	e
11	Micros 60	85	94.1	4.7	1.2	0.28	4.0	e

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	14	100.0	0.0	0.0	3.59	6.7	e
2	Sysmex X	48	100.0	0.0	0.0	3.56	1.8	e
3	Sysmex	9	88.9	0.0	11.1	3.51	2.2	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	43	100.0	0.0	0.0	3.68	2.7	e
2	Sysmex KX21	141	100.0	0.0	0.0	3.56	2.8	e
3	Sysmex PocH - 100i	199	98.0	1.5	0.5	3.69	4.8	e
4	Sysmex XP 300	624	98.7	0.5	0.8	3.56	3.2	e
5	Mythic	251	98.0	0.4	1.6	3.50	5.1	e
6	Swelab	30	96.7	0.0	3.3	3.63	4.0	e
7	Abacus Junior	4	100.0	0.0	0.0	3.67	4.0	e
8	Medonic	4	100.0	0.0	0.0	3.57	2.2	e
9	Celltac Alpha (Nihon	86	96.5	0.0	3.5	3.62	2.9	e
10	Samsung HC10	18	100.0	0.0	0.0	3.60	3.4	e
11	Micros 60	85	98.8	0.0	1.2	3.44	4.8	e

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	14	92.9	7.1	0.0	4.45	11.1	e
2	Microscopic	9	100.0	0.0	0.0	4.40	8.4	e
3	Sysmex X	48	100.0	0.0	0.0	4.70	5.1	e
4	Sysmex	9	100.0	0.0	0.0	4.47	6.9	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

Leucocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	43	100.0	0.0	0.0	4.70	6.2	e
2	Sysmex KX21	141	100.0	0.0	0.0	4.51	5.2	e
3	Sysmex PocH - 100i	199	99.5	0.0	0.5	4.50	5.9	e
4	Sysmex XP 300	624	98.7	0.5	0.8	4.55	5.3	e
5	Mythic	250	97.6	1.2	1.2	4.37	7.4	e
6	Swelab	30	90.0	0.0	10.0	4.56	5.9	e
7	Abacus Junior	4	100.0	0.0	0.0	4.32	6.2	e*
8	Medonic	4	100.0	0.0	0.0	4.20	5.2	e
9	Celltac Alpha (Nihon	86	97.6	1.2	1.2	4.64	6.9	e
10	Samsung HC10	18	94.4	5.6	0.0	4.76	9.7	e
11	Micros 60	85	97.6	1.2	1.2	4.30	7.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Automat	13	92.3	0.0	7.7	159.5	8.5	e
2	Microscopic	6	50.0	33.3	16.7	186.0	20.8	e*
3	Sysmex X	48	100.0	0.0	0.0	164.1	4.4	e
4	Sysmex	9	100.0	0.0	0.0	161.0	4.5	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex XQ-320	43	97.7	0.0	2.3	162.5	5.4	e
2	Sysmex KX21	141	99.3	0.7	0.0	168.1	6.6	e
3	Sysmex PocH - 100i	199	98.5	0.0	1.5	168.8	6.1	e
4	Sysmex XP 300	624	98.3	1.1	0.6	170.7	6.4	e
5	Mythic	251	96.8	2.0	1.2	157.0	9.9	e
6	Swelab	30	100.0	0.0	0.0	166.6	7.1	e
7	Abacus Junior	4	100.0	0.0	0.0	161.5	1.8	e
8	Medonic	4	100.0	0.0	0.0	163.0	3.9	e
9	Celltac Alpha (Nihon	86	95.3	1.2	3.5	169.6	7.5	e
10	Samsung HC10	18	88.9	0.0	11.1	162.2	4.6	e
11	Micros 60	85	96.4	1.2	2.4	159.6	10.2	e

Hemoglobin H2



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	167	97.0	0.6	2.4	97.6	3.1	e
2	Abx Micros	73	90.4	4.1	5.5	98.5	3.9	e
3	Microsemi	867	96.7	1.0	2.3	100.9	2.4	e

Hematocrit H2



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	167	94.6	3.0	2.4	0.27	4.2	e
2	Abx Micros	73	87.7	5.5	6.8	0.27	4.3	e
3	Microsemi	867	96.0	1.5	2.5	0.26	3.0	e

Leucocytes H2



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	167	97.6	1.2	1.2	4.32	5.8	e
2	Abx Micros	73	98.6	0.0	1.4	4.18	7.2	e
3	Microsemi	866	99.5	0.2	0.3	4.33	5.3	e

Thrombocytes H2



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	167	99.4	0.0	0.6	168.5	7.8	e
2	Abx Micros	73	94.6	2.7	2.7	156.2	9.1	e
3	Microsemi	865	97.7	0.5	1.8	159.1	7.2	e

Erythrocytes H2



QUALAB tolerance : 25 %

Erythrocytes H2 (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	167	97.0	0.6	2.4	3.12	4.3	e
2	Abx Micros	73	95.9	1.4	2.7	3.24	6.9	e
3	Microsemi	866	98.3	0.8	0.9	3.22	4.5	e

CRP H2



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Z3	155	90.3	3.9	5.8	22.2	9.7	e
2	Microsemi	853	94.4	2.8	2.8	29.9	9.4	e
3	Abx Micros	11	90.9	9.1	0.0	29.8	11.3	e*
4	ABX Micros CRP200	62	88.7	6.5	4.8	27.4	12.3	e

Hemoglobin BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	12	100.0	0.0	0.0	190.3	2.7	e

Hematocrit



QUALAB tolerance : 9 %

Hematocrit (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	18	100.0	0.0	0.0	0.56	2.5	e
2	EPOC	11	100.0	0.0	0.0	0.50	4.9	e*

Hemoglobin



QUALAB tolerance : 9 %

Hemoglobin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	92	100.0	0.0	0.0	134.0	1.2	e
2	Advia	4	100.0	0.0	0.0	134.0	2.8	e*
3	Yumizen/Pentra	13	100.0	0.0	0.0	136.7	2.1	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Hematocrit



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	93	97.8	2.2	0.0	0.42	2.7	e
2	Advia	4	100.0	0.0	0.0	0.42	3.3	e*
3	Yumizen/Pentra	13	92.3	7.7	0.0	0.40	3.4	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Erythrocytes



QUALAB tolerance : 25 %

Erythrocytes (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	93	100.0	0.0	0.0	4.70	1.5	e
2	Advia	4	100.0	0.0	0.0	4.71	2.6	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	4.68	3.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Leucocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	92	100.0	0.0	0.0	4.58	4.5	e
2	Advia	4	100.0	0.0	0.0	4.29	4.8	e
3	Yumizen/Pentra	13	100.0	0.0	0.0	4.21	8.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Thrombocytes



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	91	100.0	0.0	0.0	264.3	5.0	e
2	Advia	4	100.0	0.0	0.0	202.0	6.7	e*
3	Yumizen/Pentra	13	92.3	0.0	7.7	256.3	6.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Neutrophils



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	93	98.9	1.1	0.0	2.29	6.7	e
2	Advia	4	100.0	0.0	0.0	2.36	2.0	e
3	Yumizen/Pentra	12	83.3	16.7	0.0	1.73	16.9	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lymphocytes



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	93	100.0	0.0	0.0	1.76	4.7	e
2	Advia	4	100.0	0.0	0.0	1.47	9.1	e*
3	Yumizen/Pentra	12	100.0	0.0	0.0	2.04	7.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Monocytes



MQ tolerance : 40 %

Monocytes (G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	93	100.0	0.0	0.0	0.41	17.0	a
2	Advia	4	100.0	0.0	0.0	0.26	19.3	a
3	Yumizen/Pentra	12	100.0	0.0	0.0	0.32	38.0	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Eosinophils



MQ tolerance : 80 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	92	97.8	2.2	0.0	0.05	32.5	a
2	Advia	4	100.0	0.0	0.0	0.10	16.3	e
3	Yumizen/Pentra	12	91.7	0.0	8.3	0.04	31.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Basophiles



MQ tolerance : 80 %
(< 0.10: +/- 0.08 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	93	97.8	2.2	0.0	0.09	61.4	a
2	Yumizen/Pentra	12	100.0	0.0	0.0	0.05	57.2	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

MCV



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	82	100.0	0.0	0.0	88.5	2.5	e
2	Advia	4	100.0	0.0	0.0	87.8	0.9	e
3	Yumizen/Pentra	9	100.0	0.0	0.0	88.0	1.5	a

3 additional results were submitted but not published because the method groups were too small. (< results per group)

MCH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	83	100.0	0.0	0.0	28.5	1.8	e
2	Advia	4	100.0	0.0	0.0	28.9	1.6	e
3	Yumizen/Pentra	9	100.0	0.0	0.0	29.5	3.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

MCHC



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	84	100.0	0.0	0.0	322	2.8	e
2	Advia	4	100.0	0.0	0.0	330	2.5	e
3	Yumizen/Pentra	9	100.0	0.0	0.0	343	3.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

RDW



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	80	100.0	0.0	0.0	14.3	2.3	e
2	Yumizen/Pentra	8	100.0	0.0	0.0	13.4	8.2	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Immature Granulocytes



MQ tolerance : 25 %
(< 0.10: +/- 0.10 G/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	71	90.2	2.8	7.0	0.04	83.6	a

Reticulocytes



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sysmex	48	100.0	0.0	0.0	87.4	10.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Hämolyseindex Probe A



MQ tolerance : 15 %

Hämolyseindex Probe A ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	21	100.0	0.0	0.0	293.48	4.8	e
2	Architect	5	100.0	0.0	0.0	2.36	1.7	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Hämolyseindex Probe B



MQ tolerance : 15 %

Hämolyseindex Probe B ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	21	95.2	4.8	0.0	57.62	5.8	e
2	Architect	5	100.0	0.0	0.0	0.46	2.2	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Erythrocyte sedimentation rate 1h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 1h (mm/h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	MINI-CUBE	18	94.4	5.6	0.0	112	22.8	e*
2	Sarstedt Sedivette	18	94.4	0.0	5.6	59	16.1	e
3	Sarstedt Microvette	4	100.0	0.0	0.0	55	18.8	e*
4	BD Seditainer	44	86.3	2.3	11.4	62	13.2	e
5	Other methods	16	81.2	0.0	18.8	61	12.2	e

Erythrocyte sedimentation rate 2h



MQ tolerance : 40 %

Erythrocyte sedimentation rate 2h (mm/2h)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Sarstedt Sedivette	4	100.0	0.0	0.0	130	27.0	e*
2	BD Seditainer	4	75.0	25.0	0.0	130	26.1	e*
3	Other methods	6	100.0	0.0	0.0	135	14.6	e*

Hemoglobin HS



MQ tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	6	66.7	0.0	33.3	170.0	2.3	a

Hematocrit HS



MQ tolerance : 9 %

Hematocrit HS (l/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	6	66.7	0.0	33.3	0.4	1.7	e

Erythrocytes HS



MQ tolerance : 25 %

Erythrocytes HS (T/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	6	66.6	16.7	16.7	4.64	12.5	a

Leucocytes HS



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	6	100.0	0.0	0.0	7.70	10.9	a

Trombocytes HS



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	PixCell HemoScreen	6	100.0	0.0	0.0	245.5	3.4	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	333	98.8	0.3	0.9	67.3	3.5	e
2	Cobas	34	100.0	0.0	0.0	77.6	6.7	e
3	Turbidimetry	14	92.9	0.0	7.1	85.7	9.4	e
4	Afinion	1152	98.8	0.2	1.0	81.0	5.8	e
5	NycoCard SingleTest-	79	86.1	7.6	6.3	78.7	11.4	e
6	Quick Read go	93	94.6	2.2	3.2	80.8	8.2	e
7	Eurolyser	86	82.6	2.3	15.1	101.2	11.0	e
8	Fuji Dri-Chem	16	62.4	6.3	31.3	69.7	11.5	e*
9	Autolyser/DiaSys	10	80.0	10.0	10.0	72.5	11.5	e*
10	Piccolo	5	100.0	0.0	0.0	92.4	3.6	e
11	Nephelometry	5	100.0	0.0	0.0	65.0	8.6	e*
12	Celltac chemi	44	100.0	0.0	0.0	81.6	3.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	QuikRead (Vollblut)	23	95.7	0.0	4.3	134.2	5.7	e

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Lumira Dx	8	62.5	0.0	37.5	27.9	16.2	e*
2	Spinit	11	100.0	0.0	0.0	76.5	6.4	e
3	Architect	10	100.0	0.0	0.0	82.6	2.7	e
4	AQT 90 FLEX	7	100.0	0.0	0.0	76.0	6.1	e
5	Spotchem D-Concept	6	100.0	0.0	0.0	86.2	6.3	e*
6	Other methods	6	100.0	0.0	0.0	78.9	7.8	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

IgG



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	19	100.0	0.0	0.0	15.73	2.7	e
2	Nephelometry	4	100.0	0.0	0.0	16.00	2.1	e
3	Other methods	4	100.0	0.0	0.0	15.66	5.4	e*

IgA



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	17	100.0	0.0	0.0	2.53	3.0	e
2	Nephelometry	5	100.0	0.0	0.0	2.67	5.3	e*
3	Other methods	4	100.0	0.0	0.0	2.50	5.1	e*

IgM



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	18	100.0	0.0	0.0	1.18	3.4	e
2	Nephelometry	5	100.0	0.0	0.0	1.25	1.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

IgE



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	91	9.6	e*
2	Cobas	5	100.0	0.0	0.0	121	7.1	e

Alpha-1-Antitrypsin



MQ tolerance : 25 %

Alpha-1-Antitrypsin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	1.53	5.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti-Streptolysin-Antibodies



MQ tolerance : 25 %

Anti-Streptolysin-Antibodies (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	212	3.5	e
2	Other methods	4	100.0	0.0	0.0	154	4.6	e

Complement C3



QUALAB tolerance : 15 %

Complement C3 (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	18	100.0	0.0	0.0	1.90	3.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Complement C4



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	5	100.0	0.0	0.0	0.36	3.3	e
2	Other methods	14	100.0	0.0	0.0	0.34	7.8	e*

Haptoglobin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	25	100.0	0.0	0.0	1.58	3.4	e

Transferrin



MQ tolerance : 25 %

Transferrin (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	33	100.0	0.0	0.0	3.08	2.5	e

Beta-2 microglobuline



MQ tolerance : 25 %

Beta-2 microglobuline (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	2.49	3.8	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Rheumatoid factor



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Architect	5	100.0	0.0	0.0	34.0	4.4	e
2	Other methods	5	100.0	0.0	0.0	38.0	4.3	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Ceruloplasmin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Siemens	7	100.0	0.0	0.0	390.00	3.5	e
2	Other methods	4	100.0	0.0	0.0	304.00	3.1	e

Prealbumin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	16	100.0	0.0	0.0	282.70	6.8	e

Soluble transferrin receptor



MQ tolerance : 25 %

Soluble transferrin receptor (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	3.5	2.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

free light chain kappa



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Freelite	9	100.0	0.0	0.0	19	6.7	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

free light chain lambda



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Freelite	9	100.0	0.0	0.0	16	4.8	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

IgE peanut qn



MQ tolerance : 30 %

IgE peanut qn (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	13	100.0	0.0	0.0	9.27	7.1	e

IgE birch qn



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	17.54	7.2	e

IgE cat qn



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	82.71	8.6	e

IgE total



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	12	100.0	0.0	0.0	482	9.9	e

IgE sx1 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	41.00	10.4	e

IgE fx5 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	100.0	0.0	0.0	6.50	8.2	e

IgE rx1qn



MQ tolerance : 30 %

IgE rx1qn (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	4.99	11.6	e*

IgE rx2 qn



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	60.40	10.7	e*

IgE D. pteronyssinus qn



QUALAB tolerance : 30 %
(< 2: +/- 0 kU/L)

IgE D. pteronyssinus qn (kU/L)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	10	100.0	0.0	0.0	0	14.7	e*

CRP HS



QUALAB tolerance : 21 %
(< 10.00: +/- 2.00 mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Turbidimetry	9	100.0	0.0	0.0	5.30	9.9	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Lipoprotein (a)



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	63	5.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

CRP



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	133	94.7	4.5	0.8	32.0	8.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti tTG IgA



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	6	100.0	0.0	0.0	128.00	7.9	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Albumine



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	38	3.1	e
2	Cobas	27	100.0	0.0	0.0	39	2.3	e
3	Fuji Dri-Chem	251	98.4	0.4	1.2	45	4.2	e
4	Spotchem SP-4430	28	96.4	3.6	0.0	42	5.8	e
5	Spotchem D-Concept	205	94.6	4.9	0.5	47	5.7	e
6	Piccolo	64	100.0	0.0	0.0	40	3.8	e
7	Beckmann	6	83.3	16.7	0.0	37	5.7	e*
8	Skyla	4	100.0	0.0	0.0	42	1.4	e
9	Dimension	4	100.0	0.0	0.0	36	3.9	e*
10	Selectra Pro	11	90.9	0.0	9.1	38	4.1	e
11	Autolyser/DiaSys	8	100.0	0.0	0.0	39	2.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Alkaline phosphatase



QUALAB tolerance : 18 %

Alkaline phosphatase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	13	100.0	0.0	0.0	220	4.5	e
2	Cobas	29	100.0	0.0	0.0	213	4.9	e
3	Reflotron	160	92.5	5.6	1.9	236	8.2	e
4	Fuji Dri-Chem	976	98.0	0.6	1.4	196	5.7	e
5	Spotchem SP-4430	74	98.6	0.0	1.4	145	6.8	e
6	Spotchem D-Concept	458	97.6	1.1	1.3	174	5.8	e
7	Beckman	7	100.0	0.0	0.0	249	6.7	e*
8	Dimension	4	100.0	0.0	0.0	202	10.6	e*
9	Piccolo	57	98.2	0.0	1.8	236	2.8	e
10	Selectra Pro	15	80.0	6.7	13.3	244	7.5	e
11	Skyla	5	100.0	0.0	0.0	196	5.7	e*
12	Autolyser/DiaSys	18	100.0	0.0	0.0	229	6.1	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Amylase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	9	100.0	0.0	0.0	207	2.9	e
2	Cobas	9	100.0	0.0	0.0	189	1.1	e
3	Reflotron	44	95.4	2.3	2.3	198	6.6	e
4	Fuji Dri-Chem	718	99.2	0.1	0.7	192	3.6	e
5	Spotchem SP-4430	47	97.9	2.1	0.0	214	9.0	e
6	Spotchem D-Concept	343	100.0	0.0	0.0	220	5.1	e
7	Piccolo	58	100.0	0.0	0.0	161	3.5	e
8	Selectra Pro	8	100.0	0.0	0.0	244	6.4	e*
9	Autolyser/DiaSys	7	100.0	0.0	0.0	183	8.5	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Pancreatic amylase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	12	100.0	0.0	0.0	160	3.8	e
2	Cobas	13	100.0	0.0	0.0	160	1.3	e
3	Reflotron	122	98.4	0.0	1.6	168	5.8	e
4	Autolyser/DiaSys	9	88.9	0.0	11.1	149	2.2	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	16	100.0	0.0	0.0	83.0	5.6	e
2	Cobas	28	96.4	3.6	0.0	75.0	4.6	e
3	Reflotron	131	93.8	3.1	3.1	67.7	7.2	e
4	Fuji Dri-Chem	789	98.3	0.8	0.9	74.9	4.9	e
5	Spotchem SP-4430	61	95.1	1.6	3.3	80.9	6.2	e
6	Spotchem D-Concept	366	98.9	0.3	0.8	62.8	4.8	e
7	Dimension	4	100.0	0.0	0.0	82.7	3.1	e
8	Beckman	7	100.0	0.0	0.0	84.9	4.3	e
9	Piccolo	65	95.4	3.1	1.5	76.2	6.5	e
10	Selectra Pro	15	93.3	0.0	6.7	75.0	7.4	e
11	Autolyser/DiaSys	15	100.0	0.0	0.0	82.6	3.4	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin direct



MQ tolerance : 18 %

Bilirubin direct (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Autolyser/DiaSys	8	100.0	0.0	0.0	36.9	6.5	e*
2	Fuji Dri-Chem	29	89.7	3.4	6.9	37.3	7.4	e
3	Piccolo	4	100.0	0.0	0.0	29.7	11.8	e*

Calcium



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	26	100.0	0.0	0.0	2.91	2.5	e
2	Cobas	28	100.0	0.0	0.0	2.90	1.8	e
3	Fuji Dri-Chem	337	94.0	3.0	3.0	3.10	3.8	e
4	Spotchem SP-4430	14	100.0	0.0	0.0	2.66	3.6	e
5	Spotchem D-Concept	76	81.6	10.5	7.9	2.16	5.7	e
6	Piccolo	55	100.0	0.0	0.0	2.91	3.0	e
7	Selectra Pro	7	100.0	0.0	0.0	2.93	2.9	e*
8	Autolyser/DiaSys	8	100.0	0.0	0.0	2.77	2.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium ISE



MQ tolerance : 12 %

Calcium ISE (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	5	100.0	0.0	0.0	1.19	1.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Chloride



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	28	100.0	0.0	0.0	108	2.1	e
2	Cobas	18	100.0	0.0	0.0	105	1.3	e
3	Fuji Dri-Chem	882	96.2	1.6	2.2	108	2.0	e
4	Spotchem D-Concept	391	98.9	0.3	0.8	117	1.7	e
5	Spotchem EL-SE 1520	69	85.6	7.2	7.2	118	2.6	e
6	Piccolo	26	100.0	0.0	0.0	107	1.9	e
7	iStat Chem8	5	100.0	0.0	0.0	112	0.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total



QUALAB tolerance : 10 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	24	100.0	0.0	0.0	5.86	3.0	e
2	Cobas	26	100.0	0.0	0.0	5.72	2.3	e
3	Reflotron	83	92.8	3.6	3.6	5.31	4.9	e
4	Fuji Dri-Chem	933	98.0	1.4	0.6	5.59	4.0	e
5	Spotchem SP-4430	81	100.0	0.0	0.0	5.30	3.7	e
6	Spotchem D-Concept	425	96.7	1.4	1.9	5.19	4.0	e
7	Piccolo	31	100.0	0.0	0.0	5.65	1.8	e
8	Cholestech LDX	296	94.6	2.7	2.7	5.62	4.2	e
9	Selectra Pro	13	92.3	7.7	0.0	5.97	5.3	e*
10	Autolyser/DiaSys	18	100.0	0.0	0.0	5.79	3.5	e
11	Other methods	4	100.0	0.0	0.0	5.08	1.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterin HDL



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Wet chemistry, direc	5	100.0	0.0	0.0	1.47	5.7	e*
2	Cobas	24	100.0	0.0	0.0	0.93	4.5	e
3	Reflotron	43	86.0	7.0	7.0	1.06	9.9	e
4	Fuji Dri-Chem	902	98.7	0.1	1.2	1.32	3.4	e
5	Spotchem SP-4430	72	98.6	0.0	1.4	0.94	8.1	e
6	Spotchem D-Concept	404	97.6	1.2	1.2	0.96	7.6	e
7	Dimension	5	100.0	0.0	0.0	1.27	7.3	e*
8	Piccolo	28	96.4	3.6	0.0	1.03	9.7	e
9	Pentra/Selectra	10	100.0	0.0	0.0	1.23	7.4	e
10	Cholestech LDX	296	94.3	2.7	3.0	1.13	8.4	e
11	Architect	13	100.0	0.0	0.0	1.40	1.7	e
12	Autolyser/DiaSys	18	100.0	0.0	0.0	1.24	8.4	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatine kinase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	18	100.0	0.0	0.0	418	2.7	e
2	Cobas	26	100.0	0.0	0.0	399	3.6	e
3	Reflotron	4	75.0	0.0	25.0	355	13.3	e*
4	Fuji Dri-Chem	643	97.0	1.6	1.4	447	4.6	e
5	Spotchem SP-4430	43	97.7	2.3	0.0	413	6.4	e
6	Spotchem D-Concept	270	99.2	0.4	0.4	393	5.3	e
7	Piccolo	22	100.0	0.0	0.0	403	3.6	e
8	Selectra Pro	11	100.0	0.0	0.0	424	6.1	e
9	Dimension	4	100.0	0.0	0.0	395	4.6	e*
10	Autolyser/DiaSys	15	100.0	0.0	0.0	406	4.8	e
11	Other methods	4	100.0	0.0	0.0	421	1.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol LDL



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Selectra	6	100.0	0.0	0.0	3.7	11.4	e*
2	Standard chemistry	14	100.0	0.0	0.0	3.7	1.9	e
3	Roche, Cobas	14	100.0	0.0	0.0	3.7	3.1	e
4	Autolyser/DiaSys	11	90.9	9.1	0.0	3.6	9.3	e*
5	Beckman	4	100.0	0.0	0.0	3.9	3.6	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Iron



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	14	100.0	0.0	0.0	35	2.2	e
2	Cobas	17	100.0	0.0	0.0	34	1.6	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Gamma-glutamyltransferase



QUALAB tolerance : 18 %

Gamma-glutamyltransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	29	100.0	0.0	0.0	99	6.9	e
2	Reflotron	235	96.1	0.9	3.0	135	5.8	e
3	Fuji Dri-Chem	1078	98.6	0.5	0.9	125	5.3	e
4	Spotchem SP-4430	107	99.1	0.9	0.0	132	6.7	e
5	Spotchem D-Concept	520	98.0	1.2	0.8	127	6.9	e
6	Selectra/Biolis	4	100.0	0.0	0.0	106	4.4	e*
7	Architect	12	100.0	0.0	0.0	100	5.5	e
8	Dimension	5	100.0	0.0	0.0	106	7.1	e*
9	IFCC Beckmann	6	100.0	0.0	0.0	105	1.9	e
10	Piccolo	61	100.0	0.0	0.0	94	3.4	e
11	Skyla	4	100.0	0.0	0.0	104	2.9	e
12	Selectra Pro	11	90.9	0.0	9.1	106	6.0	e
13	Autolyser/DiaSys	18	100.0	0.0	0.0	105	3.7	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	25	100.0	0.0	0.0	13.2	2.2	e
2	Cobas	28	100.0	0.0	0.0	13.0	1.9	e
3	Reflotron	237	89.0	5.9	5.1	12.2	4.5	e
4	Fuji Dri-Chem	1013	99.0	0.3	0.7	11.7	2.3	e
5	Spotchem SP-4430	93	94.6	2.2	3.2	13.1	4.2	e
6	Spotchem D-Concept	483	95.5	3.5	1.0	12.2	4.4	e
7	Dimension	4	100.0	0.0	0.0	13.4	1.5	e
8	Piccolo	73	100.0	0.0	0.0	12.8	0.9	e
9	Cholestech LDX	290	92.5	4.1	3.4	11.9	4.4	e
10	Selectra Pro	16	100.0	0.0	0.0	12.7	4.4	e*
11	Autolyser/DiaSys	17	100.0	0.0	0.0	12.5	3.6	e
12	iStat Chem8	7	100.0	0.0	0.0	11.6	1.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Accu-Chek Instant	116	96.6	1.7	1.7	11.7	3.0	e
2	Accu-Chek Aviva	234	90.6	3.8	5.6	13.7	3.8	e
3	Accu-Chek Inform 2	805	99.5	0.4	0.1	14.2	2.8	e
4	Accu-Check Guide	290	96.2	1.4	2.4	11.6	3.1	e
5	Contour XT	1301	96.5	2.2	1.3	12.7	4.0	e
6	Skyla	6	100.0	0.0	0.0	13.7	2.2	e
7	Statstrip/Xpress	101	100.0	0.0	0.0	11.0	1.9	e
8	Glucocard	9	88.9	11.1	0.0	19.3	4.9	e*
9	Hemocue 201+ P-equiv	103	95.1	1.0	3.9	13.9	2.3	e
10	Hemocue 201RT P-equi	134	96.3	1.5	2.2	13.8	2.6	e
11	Contour NEXT	16	100.0	0.0	0.0	12.2	3.0	e

12 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Hemocue 201+ (alt)	34	97.1	0.0	2.9	13.8	3.5	e
2	AccuChek Sensor	30	100.0	0.0	0.0	13.0	2.9	e
3	OneTouch Verio	24	95.8	0.0	4.2	13.0	2.5	e
4	Contour 2 (5s)	11	63.6	18.2	18.2	10.3	6.0	e*
5	Healthpro	25	84.0	4.0	12.0	21.3	4.7	e
6	Mylife UNIO	387	94.4	2.8	2.8	15.5	3.9	e
7	mylife Pura	93	90.3	4.3	5.4	14.1	4.7	e
8	Alpha Check	22	72.7	18.2	9.1	20.8	7.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Uric Acid



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	28	96.4	0.0	3.6	445	2.6	e
2	Cobas	25	100.0	0.0	0.0	435	1.9	e
3	Reflotron	177	94.9	2.3	2.8	445	4.9	e
4	Fuji Dri-Chem	1000	97.8	0.7	1.5	476	2.7	e
5	Spotchem SP-4430	86	97.6	1.2	1.2	397	4.4	e
6	Spotchem D-Concept	485	98.4	0.2	1.4	400	3.3	e
7	Piccolo	37	89.2	8.1	2.7	408	5.9	e
8	Skyla	5	100.0	0.0	0.0	446	2.6	e
9	Selectra Pro	17	94.1	0.0	5.9	441	3.6	e
10	Autolyser/DiaSys	17	94.1	0.0	5.9	417	4.2	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Urea



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	24	100.0	0.0	0.0	19.3	3.0	e
2	Cobas	26	100.0	0.0	0.0	18.6	2.8	e
3	Reflotron	86	88.4	2.3	9.3	19.6	7.0	e
4	Fuji Dri-Chem	612	99.7	0.0	0.3	19.7	2.3	e
5	Spotchem SP-4430	51	92.1	2.0	5.9	16.9	5.8	e
6	Spotchem D-Concept	278	93.8	4.0	2.2	18.6	7.5	e
7	Piccolo	63	100.0	0.0	0.0	18.6	2.4	e
8	Skyla	6	100.0	0.0	0.0	16.5	3.6	e
9	Selectra Pro	9	100.0	0.0	0.0	18.2	6.2	e*
10	Autolyser/DiaSys	13	100.0	0.0	0.0	18.7	5.0	e
11	iStat Chem8	6	100.0	0.0	0.0	25.1	3.5	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Potassium



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	37	97.3	2.7	0.0	5.75	2.5	e
2	Cobas	28	100.0	0.0	0.0	5.79	1.3	e
3	Reflotron	200	87.5	6.0	6.5	6.17	3.5	e
4	Fuji Dri-Chem	1052	97.1	1.1	1.8	5.74	1.7	e
5	Spotchem D-Concept	487	99.0	0.6	0.4	5.41	1.7	e
6	Autolyser/DiaSys	7	85.7	0.0	14.3	5.88	3.2	e*
7	Spotchem EL-SE 1520	80	95.0	2.5	2.5	5.32	2.3	e
8	Piccolo	42	97.6	2.4	0.0	6.14	3.2	e
9	iStat Chem8	8	100.0	0.0	0.0	5.60	0.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	363	2.6	e
2	Cobas	27	100.0	0.0	0.0	352	4.7	e
3	Reflotron	312	97.4	1.0	1.6	404	5.8	e
4	Fuji Dri-Chem	1103	99.0	0.3	0.7	342	4.1	e
5	Spotchem SP-4430	117	100.0	0.0	0.0	335	2.8	e
6	Spotchem D-Concept	522	98.7	0.2	1.1	327	2.9	e
7	Jaffé Boehringer	4	100.0	0.0	0.0	351	2.9	e
8	Enzymatic	9	100.0	0.0	0.0	374	1.7	e
9	Piccolo	70	100.0	0.0	0.0	362	3.9	e
10	Selectra Pro	17	94.1	5.9	0.0	365	7.7	e
11	Skyla	5	80.0	20.0	0.0	365	10.8	e*
12	Autolyser/DiaSys	18	100.0	0.0	0.0	366	3.9	e
13	Other methods	6	100.0	0.0	0.0	372	2.4	e
14	EPOC	10	100.0	0.0	0.0	319	9.8	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Creatinine E



QUALAB tolerance : 18 %

Creatinine E (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat Chem8	14	100.0	0.0	0.0	379	5.1	e
2	ABL700/800	10	100.0	0.0	0.0	386	6.4	e

eGFR CKD-EPI



MQ tolerance : 30 %

eGFR CKD-EPI ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	64	96.9	0.0	3.1	12	6.5	e
2	Reflotron	83	97.6	1.2	1.2	11	8.8	e
3	Fuji Dri-Chem	400	95.0	2.5	2.5	14	8.9	e
4	Spotchem	239	91.2	2.1	6.7	14	7.9	e

eGFR Cockcroft-Gault



MQ tolerance : 30 %

eGFR Cockcroft-Gault ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	5	100.0	0.0	0.0	16	15.4	e*
2	Reflotron	9	100.0	0.0	0.0	14	11.5	e*
3	Fuji Dri-Chem	35	88.5	2.9	8.6	15	14.0	e
4	Spotchem	10	100.0	0.0	0.0	15	11.6	e*

eGFR MDRD



MQ tolerance : 30 %

eGFR MDRD ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	4	100.0	0.0	0.0	13	3.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

LDH



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC	39	97.4	2.6	0.0	287	5.5	e
2	Cobas	11	100.0	0.0	0.0	289	2.9	e
3	Fuji Dri-Chem	140	97.9	0.0	2.1	247	4.5	e
4	Spotchem SP-4430	11	90.9	9.1	0.0	204	11.1	e*
5	Spotchem D-Concept	47	97.9	2.1	0.0	245	7.8	e
6	Piccolo	4	100.0	0.0	0.0	238	3.3	e
7	Autolyser/DiaSys	6	100.0	0.0	0.0	298	4.6	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Magnesium



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	21	100.0	0.0	0.0	1.28	3.1	e
2	Cobas	19	100.0	0.0	0.0	1.30	2.4	e
3	Fuji Dri-Chem	97	97.9	2.1	0.0	1.44	3.8	e
4	Spotchem D-Concept	37	100.0	0.0	0.0	1.11	4.6	e
5	Spotchem SP-4430	4	100.0	0.0	0.0	1.09	4.6	e*
6	Beckman	4	100.0	0.0	0.0	1.32	3.5	e*
7	Piccolo	5	100.0	0.0	0.0	1.38	2.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	37	100.0	0.0	0.0	151	1.8	e
2	Cobas	28	96.4	0.0	3.6	150	1.2	e
3	Fuji Dri-Chem	962	97.0	1.5	1.5	153	1.6	e
4	Spotchem D-Concept	427	99.8	0.0	0.2	149	1.2	e
5	Spotchem EL-SE 1520	74	95.9	1.4	2.7	146	1.8	e
6	Piccolo	42	100.0	0.0	0.0	149	1.2	e
7	iStat Chem8	7	100.0	0.0	0.0	149	0.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Phosphate



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	22	100.0	0.0	0.0	1.8	3.2	e
2	Cobas	23	100.0	0.0	0.0	1.8	1.8	e
3	Fuji Dri-Chem	82	98.8	0.0	1.2	1.9	3.2	e
4	Spotchem D-Concept	15	93.3	0.0	6.7	1.9	3.5	e
5	Spotchem SP-4430	4	100.0	0.0	0.0	1.8	2.7	e
6	Piccolo	9	100.0	0.0	0.0	2.2	2.7	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Protein total



QUALAB tolerance : 12 %

Protein total (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	23	100.0	0.0	0.0	61.2	2.7	e
2	Cobas	23	100.0	0.0	0.0	59.5	2.7	e
3	Fuji Dri-Chem	197	97.0	1.0	2.0	56.5	3.5	e
4	Spotchem SP-4430	24	100.0	0.0	0.0	58.1	5.6	e
5	Spotchem D-Concept	163	92.1	6.7	1.2	54.1	6.3	e
6	Piccolo	52	96.2	0.0	3.8	61.1	1.6	e
7	Skyla	5	100.0	0.0	0.0	53.0	7.4	e*
8	Selectra Pro	8	100.0	0.0	0.0	57.6	3.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Aspartate aminotransferase



QUALAB tolerance : 18 %

Aspartate aminotransferase (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC with PP	26	100.0	0.0	0.0	178	4.8	e
2	Cobas	25	100.0	0.0	0.0	177	4.6	e
3	Reflotron	244	93.4	3.3	3.3	182	7.8	e
4	Fuji Dri-Chem	1082	99.1	0.8	0.1	166	4.5	e
5	Spotchem SP-4430	115	100.0	0.0	0.0	135	5.4	e
6	Spotchem D-Concept	518	98.8	0.4	0.8	137	4.5	e
7	IFCC without PP	4	100.0	0.0	0.0	163	2.1	e
8	Piccolo	77	98.7	0.0	1.3	154	3.8	e
9	Skyla	6	100.0	0.0	0.0	161	5.1	e
10	Selectra Pro	16	100.0	0.0	0.0	175	6.2	e
11	Autolyser/DiaSys	18	94.4	0.0	5.6	170	3.3	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Alanine aminotransferase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	IFCC with PP	21	95.2	4.8	0.0	122	5.8	e
2	Cobas	29	100.0	0.0	0.0	115	3.0	e
3	Reflotron	247	95.6	0.8	3.6	101	5.5	e
4	Fuji Dri-Chem	1095	98.6	0.5	0.9	118	5.3	e
5	Spotchem SP-4430	115	98.3	1.7	0.0	91	5.9	e
6	Spotchem D-Concept	527	98.5	0.4	1.1	78	5.3	e
7	Piccolo	75	98.7	0.0	1.3	101	4.8	e
8	Skyla	6	83.3	16.7	0.0	107	9.7	e*
9	Selectra Pro	16	100.0	0.0	0.0	118	4.8	e
10	Autolyser/DiaSys	18	100.0	0.0	0.0	121	3.8	e
11	Other methods	5	100.0	0.0	0.0	126	1.3	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Triglycerides



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	24	100.0	0.0	0.0	1.92	6.1	e
2	Cobas	26	100.0	0.0	0.0	1.94	2.6	e
3	Reflotron	23	91.4	4.3	4.3	2.12	8.4	e
4	Fuji Dri-Chem	917	98.0	1.0	1.0	1.95	4.8	e
5	Spotchem SP-4430	78	96.2	0.0	3.8	1.92	4.6	e
6	Spotchem D-Concept	412	96.8	0.0	3.2	1.95	4.4	e
7	Piccolo	28	96.4	0.0	3.6	2.19	2.1	e
8	Cholestech LDX	297	96.9	0.7	2.4	1.82	4.3	e
9	Selectra Pro	13	92.3	0.0	7.7	1.98	3.8	e
10	Autolyser/DiaSys	18	94.4	5.6	0.0	1.89	8.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Lithium



QUALAB tolerance : 15 %

Lithium (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas Integra 800/40	5	100.0	0.0	0.0	1.48	1.5	e
2	Other methods	17	100.0	0.0	0.0	1.46	4.2	e

Lactate



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	16	100.0	0.0	0.0	4.38	4.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample A



QUALAB tolerance : 9 %
(< 5.0: +/- 0.5 %)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	18	94.4	5.6	0.0	4.9	5.8	e*
2	HPLC	8	100.0	0.0	0.0	5.1	3.0	e
3	Afinion	560	98.9	0.7	0.4	5.1	2.8	e
4	Cobas b101	148	99.3	0.0	0.7	4.8	3.6	e
5	DCA2000/Vantage	146	92.5	3.4	4.1	5.3	4.2	e
6	Celltac chemi	22	100.0	0.0	0.0	4.8	3.2	e
7	NycoCard	12	75.0	8.3	16.7	5.6	6.5	e*
8	Eurolyser	12	58.3	25.0	16.7	5.2	5.1	c
9	A1c Now	216	68.1	16.2	15.7	5.2	4.7	c
10	AFIAS	73	89.1	8.2	2.7	4.9	5.6	e
11	Others	24	91.7	8.3	0.0	5.1	5.2	e
12	Spinit	11	100.0	0.0	0.0	5.2	2.4	c

3 additional results were submitted but not published because the method groups were too small. (< results per group)

HbA1c sample B



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	17	88.2	11.8	0.0	5.3	5.4	e*
2	HPLC	9	100.0	0.0	0.0	5.5	2.2	e
3	Afinion	777	98.5	1.4	0.1	5.3	2.9	e
4	Cobas b101	169	98.8	0.6	0.6	5.1	3.8	e
5	DCA2000/Vantage	228	96.9	1.3	1.8	5.5	3.2	e
6	Celltac chemi	15	100.0	0.0	0.0	5.0	2.6	e
7	NycoCard	9	55.6	22.2	22.2	5.4	6.5	c
8	Eurolyser	6	50.0	33.3	16.7	5.4	5.7	c
9	A1c Now	8	100.0	0.0	0.0	5.4	4.1	c
10	AFIAS	102	93.1	6.9	0.0	5.2	4.7	e
11	Spinit	6	100.0	0.0	0.0	5.4	3.5	c
12	Others	18	94.4	5.6	0.0	5.3	4.6	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

pCO2



QUALAB tolerance : 12 %

pCO2 (kPa)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	100	100.0	0.0	0.0	2.89	3.0	e
2	ABL80 FLEX	5	100.0	0.0	0.0	2.89	6.2	e*
3	ABL80 FLEX CO-OX / O	6	83.3	0.0	16.7	3.02	3.9	e*
4	ABL90 FLEX / PLUS	104	98.1	0.0	1.9	3.05	2.4	e
5	Cobas b 123	11	100.0	0.0	0.0	3.02	3.0	e
6	Cobas b 221	8	87.5	12.5	0.0	3.09	7.2	e*
7	GEM	7	100.0	0.0	0.0	2.80	2.5	e
8	iStat	43	95.4	2.3	2.3	2.63	4.0	e
9	EPOC	52	63.5	26.9	9.6	2.00	10.3	e
10	IL	4	100.0	0.0	0.0	2.85	2.0	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

pO2



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	99	88.9	7.1	4.0	9.84	6.4	e
2	ABL80 FLEX	4	100.0	0.0	0.0	9.02	3.7	e*
3	ABL80 FLEX CO-OX / O	6	83.3	0.0	16.7	7.86	8.8	e*
4	ABL90 FLEX / PLUS	104	89.4	1.0	9.6	7.43	4.5	e
5	Cobas b 123	13	84.6	7.7	7.7	8.98	7.7	e*
6	Cobas b 221	5	60.0	40.0	0.0	10.95	15.3	e*
7	GEM	6	100.0	0.0	0.0	9.30	7.9	e*
8	iStat	41	90.2	9.8	0.0	11.72	8.6	e
9	EPOC	52	67.3	5.8	26.9	8.47	8.9	e
10	IL	4	100.0	0.0	0.0	9.40	3.9	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

pH



QUALAB tolerance : 1 %

pH ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	99	100.0	0.0	0.0	7.57	0.1	e
2	ABL80 FLEX	6	100.0	0.0	0.0	7.61	0.2	e
3	ABL80 FLEX CO-OX / O	5	100.0	0.0	0.0	7.59	0.1	e
4	ABL90 FLEX / PLUS	105	99.0	0.0	1.0	7.59	0.1	e
5	Cobas b 123	12	100.0	0.0	0.0	7.57	0.1	e
6	Cobas b 221	9	88.9	11.1	0.0	7.57	0.3	e
7	GEM	7	100.0	0.0	0.0	7.64	0.1	e
8	iStat	44	100.0	0.0	0.0	7.65	0.1	e
9	EPOC	51	100.0	0.0	0.0	7.65	0.2	e
10	IL	4	100.0	0.0	0.0	7.64	0.1	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 221	4	100.0	0.0	0.0	15.3	2.2	e*
2	Cobas b 123	10	100.0	0.0	0.0	14.1	2.7	e
3	iStat	10	100.0	0.0	0.0	13.3	0.7	e
4	EPOC	40	95.0	5.0	0.0	14.3	4.3	e
5	ABL700/800	91	100.0	0.0	0.0	14.1	2.0	e
6	ABL90 FLEX / PLUS	92	100.0	0.0	0.0	13.6	1.7	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Hemoglobin BG



QUALAB tolerance : 9 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	90	98.9	1.1	0.0	191.7	2.1	e
2	ABL90 FLEX / PLUS	89	96.6	0.0	3.4	192.4	0.4	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	190.0	1.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Potassium BG



QUALAB tolerance : 6 %

Potassium BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 221	4	100.0	0.0	0.0	5.4	2.2	e*
2	Cobas b 123	16	100.0	0.0	0.0	5.4	1.1	e
3	iStat	18	100.0	0.0	0.0	5.3	0.8	e
4	EPOC	45	100.0	0.0	0.0	5.0	1.6	e
5	ABL700/800	92	100.0	0.0	0.0	5.5	1.2	e
6	ABL90 FLEX / PLUS	102	98.0	1.0	1.0	5.4	1.2	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium BG



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 221	4	100.0	0.0	0.0	124.9	1.2	e
2	Cobas b 123	16	100.0	0.0	0.0	122.6	1.6	e
3	iStat	18	100.0	0.0	0.0	125.0	0.5	e
4	EPOC	43	100.0	0.0	0.0	119.6	0.7	e
5	ABL700/800	90	100.0	0.0	0.0	126.6	0.8	e
6	ABL90 FLEX / PLUS	101	99.0	0.0	1.0	126.0	0.7	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Chlorid-BG



QUALAB tolerance : 6 %

Chlorid-BG (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b 123	10	100.0	0.0	0.0	70.8	1.5	e
2	EPOC	13	100.0	0.0	0.0	72.2	1.4	e
3	ABL700/800	83	100.0	0.0	0.0	67.3	2.3	e
4	ABL90 FLEX / PLUS	95	96.8	0.0	3.2	64.1	1.5	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Calcium-BG



MQ tolerance : 12 %
(< 2.00: +/- 0.24 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	4	100.0	0.0	0.0	0.27	8.3	e*
2	ABL80 FLEX	4	100.0	0.0	0.0	0.28	20.2	e*
3	Cobas b123	10	100.0	0.0	0.0	0.18	31.3	e*
4	Roche, Cobas	7	100.0	0.0	0.0	0.27	26.9	e*
5	iStat	13	100.0	0.0	0.0	0.30	3.2	e
6	EPOC	40	97.5	0.0	2.5	0.25	6.8	e
7	ABL700/800	92	100.0	0.0	0.0	0.37	4.9	e
8	ABL90 FLEX / PLUS	96	100.0	0.0	0.0	0.38	5.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FHHb



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	4	100.0	0.0	0.0	20.900	0.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lactate-BG



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	GEM	4	75.0	0.0	25.0	11.80	1.3	e
2	Cobas b123	8	100.0	0.0	0.0	11.00	6.9	e*
3	Roche, Cobas	6	100.0	0.0	0.0	11.83	5.1	e
4	IL	4	100.0	0.0	0.0	11.70	4.8	e*
5	EPOC	39	94.8	2.6	2.6	9.91	9.7	e
6	iStat	13	100.0	0.0	0.0	10.77	1.2	e
7	ABL700/800	92	100.0	0.0	0.0	10.36	4.9	e
8	ABL90 FLEX / PLUS	94	100.0	0.0	0.0	10.39	3.5	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

sO2 OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	iStat	14	100.0	0.0	0.0	98.714	0.5	e
2	ABL700/800	80	100.0	0.0	0.0	70.078	0.1	e
3	ABL90 FLEX / PLUS	83	97.6	0.0	2.4	70.053	0.1	e
4	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	70.050	0.2	e

FO2Hb OR



MQ tolerance : 20 %

FO2Hb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	77	100.0	0.0	0.0	48.890	0.2	e
2	ABL90 FLEX / PLUS	84	98.8	0.0	1.2	48.921	1.2	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	49.000	0.2	e

FCOHb OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	80	100.0	0.0	0.0	20.241	1.0	e
2	ABL90 FLEX / PLUS	83	98.8	0.0	1.2	20.092	0.8	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	20.050	1.2	e

FMetHb OR



MQ tolerance : 20 %

FMetHb OR (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	80	100.0	0.0	0.0	9.998	0.8	e
2	ABL90 FLEX / PLUS	83	98.8	0.0	1.2	9.971	1.2	e
3	ABL80 FLEX CO-OX / O	4	100.0	0.0	0.0	10.000	0.0	e

FHbF OR



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	32	96.9	0.0	3.1	51.065	3.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin OR



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL90 FLEX / PLUS	33	97.0	0.0	3.0	441.6	3.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Troponin I



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Vidas	12	100.0	0.0	0.0	5459.8	11.4	e*
2	Architect High Sensi	9	100.0	0.0	0.0	2092.0	7.5	e
3	Other methods	9	88.9	0.0	11.1	4153.0	8.5	e
4	AQT 90 FLEX	4	100.0	0.0	0.0	345.0	2.8	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Troponin T



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas hs	10	100.0	0.0	0.0	1140.60	7.7	e
2	Cobas hs STAT	9	100.0	0.0	0.0	1113.00	5.3	e
3	Cobas E / Elecsys	4	100.0	0.0	0.0	685.40	13.7	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Myoglobin



QUALAB tolerance : 30 %

Myoglobin (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	101.0	3.8	e
2	Architect	5	100.0	0.0	0.0	122.0	9.9	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

CK-MB mass



MQ tolerance : 40 %

CK-MB mass (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	7	100.0	0.0	0.0	11.7	11.0	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	100.0	0.0	0.0	340.5	13.0	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

NT-proBNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Pathfast	7	85.7	14.3	0.0	718.0	15.7	e*
2	AQT 90 FLEX	4	100.0	0.0	0.0	482.0	2.7	e
3	VIDAS	9	100.0	0.0	0.0	213.0	8.3	e
4	Other methods	4	100.0	0.0	0.0	377.0	4.7	e
5	Cobas E / Elecsys	20	100.0	0.0	0.0	268.0	8.9	a
6	Architect	8	100.0	0.0	0.0	298.0	4.6	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

TSH



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	21	100.0	0.0	0.0	3.81	4.3	e
2	Architect	11	100.0	0.0	0.0	2.89	4.3	e
3	VIDAS	15	100.0	0.0	0.0	3.92	7.4	e
4	Dimension	4	100.0	0.0	0.0	3.40	2.3	e
5	AFIAS	30	93.4	3.3	3.3	4.02	5.9	e
6	Other methods	5	80.0	0.0	20.0	3.41	6.0	e*

4 additional results were submitted but not published because the method groups were too small. (< results per group)

T3



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	7	85.7	14.3	0.0	1.4	13.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

T4



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	7	100.0	0.0	0.0	164	11.1	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

FT3



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	20	100.0	0.0	0.0	6.7	3.7	e
2	Architect	10	100.0	0.0	0.0	5.6	5.4	e
3	VIDAS	7	100.0	0.0	0.0	5.6	6.4	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

FT4



QUALAB tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	20	100.0	0.0	0.0	27.1	4.8	e
2	Architect	11	100.0	0.0	0.0	20.0	2.3	e
3	VIDAS	8	100.0	0.0	0.0	25.8	8.0	e*
4	Other methods	6	100.0	0.0	0.0	24.9	3.8	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Testosterone



QUALAB tolerance : 30 %

Testosterone (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	10	100.0	0.0	0.0	9.8	5.7	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

Estradiol



QUALAB tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	794	4.1	e
2	ADVIA Centaur XP/CP	4	100.0	0.0	0.0	1101	12.0	e*
3	Architect	7	100.0	0.0	0.0	732	2.3	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

SHBG



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	10	100.0	0.0	0.0	26.8	2.2	e
2	Architect	4	100.0	0.0	0.0	31.1	4.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Cortisol



QUALAB tolerance : 20 %

Cortisol (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	17	100.0	0.0	0.0	343	3.4	e
2	Architect	5	100.0	0.0	0.0	330	2.3	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Progesteron



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	21.4	6.9	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

DHEAS



MQ tolerance : 30 %

DHEAS (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	4.26	6.8	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Luteinizing hormone



QUALAB tolerance : 24 %

Luteinizing hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	9	100.0	0.0	0.0	15.2	7.8	e
2	Architect	5	100.0	0.0	0.0	9.8	7.0	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Follicle-stimulating hormone



QUALAB tolerance : 24 %

Follicle-stimulating hormone (U/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	9	100.0	0.0	0.0	12.2	7.8	e
2	Architect	6	100.0	0.0	0.0	12.5	4.9	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

Prolactine



QUALAB tolerance : 24 %

Prolactine (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas/Roche	11	100.0	0.0	0.0	18.8	4.7	e
2	Architect	6	100.0	0.0	0.0	16.6	5.4	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Insulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	12	100.0	0.0	0.0	347	4.9	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

HGH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	8.66	4.8	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Freies Testosteron



MQ tolerance : 25 %

Freies Testosteron (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	21.2	14.5	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

IGF-1



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	5	100.0	0.0	0.0	93	8.3	e*
2	Other methods	5	100.0	0.0	0.0	62	15.0	a

Troponin T CR



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	1325	97.0	2.4	0.6	230.76	10.5	e

D-dimer CR



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	1300	90.3	6.2	3.5	0.62	11.5	e
2	Lumira Dx	7	85.7	0.0	14.3	0.70	4.7	a

CKMB- K8



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	10	90.0	0.0	10.0	22.1	13.4	e

NT-proBNP CR



QUALAB tolerance : 27 %

NT-proBNP CR (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas h 232	829	96.0	2.8	1.2	426	13.6	e

PCO2 CCA



QUALAB tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	13	76.9	7.7	15.4	5.29	8.0	e*

PO2 CCA



QUALAB tolerance : 15 %

PO2 CCA (kPa)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	13	76.9	7.7	15.4	13.13	7.8	e*

pH CCA



QUALAB tolerance : 1 %

pH CCA ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	12	91.7	0.0	8.3	7.41	0.2	e

Potassium CCA



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	6	100.0	0.0	0.0	4.8	1.6	e

Sodium CCA



QUALAB tolerance : 6 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	OPTI CCA	5	100.0	0.0	0.0	146.5	0.9	e

Ferritin



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Dimension	4	100.0	0.0	0.0	75.00	5.2	e
2	Beckman	8	100.0	0.0	0.0	60.15	6.3	e
3	Cobas E / Elecsys	21	100.0	0.0	0.0	72.19	4.3	e
4	Architect	12	100.0	0.0	0.0	85.81	6.6	e
5	Mini Vidas	9	100.0	0.0	0.0	51.00	6.5	e
6	AFIAS	39	100.0	0.0	0.0	66.02	4.7	e
7	Eurolyser	16	100.0	0.0	0.0	51.07	9.5	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Vitamin B12



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	6	100.0	0.0	0.0	217.45	6.3	e*
2	Cobas E / Elecsys	18	100.0	0.0	0.0	242.23	7.5	e
3	Architect	11	100.0	0.0	0.0	214.52	11.5	e*

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Folate



QUALAB tolerance : 24 %
(< 10.00: +/- 2.40 nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	5	100.0	0.0	0.0	6.67	14.0	e*
2	Cobas E / Elecsys	19	100.0	0.0	0.0	7.54	11.2	e
3	Architect	10	100.0	0.0	0.0	11.40	9.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Holotranscobalamine



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Architect	14	100.0	0.0	0.0	63.4	10.0	e
2	Other methods	21	90.5	9.5	0.0	53.0	12.4	e

Bilirubin total Neo



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	16	100.0	0.0	0.0	99	6.2	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin direct



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	18	94.4	0.0	5.6	53	7.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Bilirubin neonatal



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ABL700/800	10	100.0	0.0	0.0	111	6.3	e
2	Other methods	11	100.0	0.0	0.0	127	5.2	e

PSA



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	19	100.0	0.0	0.0	5.43	3.6	e
2	Architect	7	100.0	0.0	0.0	4.97	5.1	e
3	AFIAS	22	100.0	0.0	0.0	5.48	6.7	e

10 additional results were submitted but not published because the method groups were too small. (< results per group)

free PSA



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	10	100.0	0.0	0.0	2.00	1.9	e
2	Architect	5	100.0	0.0	0.0	2.22	4.4	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

CEA



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	12	100.0	0.0	0.0	14.0	4.3	e
2	Architect	7	100.0	0.0	0.0	20.8	7.2	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 125



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	8	100.0	0.0	0.0	144.9	6.0	e

8 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 19-9



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	6	100.0	0.0	0.0	30.4	9.2	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

CA 15-3



MQ tolerance : 25 %

CA 15-3 (kIU/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	10	100.0	0.0	0.0	67.8	7.3	e
2	Architect	4	100.0	0.0	0.0	77.8	3.1	e

6 additional results were submitted but not published because the method groups were too small. (< results per group)

AFP



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	7	100.0	0.0	0.0	93.8	12.6	e*
2	Architect	4	100.0	0.0	0.0	92.4	9.3	e*

5 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG qn



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas E / Elecsys	12	100.0	0.0	0.0	108.8	3.0	e
2	VIDAS	8	100.0	0.0	0.0	51.5	12.3	e*
3	Architect	7	100.0	0.0	0.0	90.7	4.8	e
4	AFIAS	7	100.0	0.0	0.0	188.0	6.4	e

9 additional results were submitted but not published because the method groups were too small. (< results per group)

HCG intact



QUALAB tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	39.0	4.8	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

S100



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	2.05	4.9	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

NSE



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	3.0	11.3	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Thyreoglobulin



MQ tolerance : 25 %

Thyreoglobulin (µg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	31.3	6.6	e*
2	Other methods	4	100.0	0.0	0.0	53.0	14.0	e*

CK-MB



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Fuji Dri-Chem	27	96.3	0.0	3.7	53.1	8.2	e
2	Cobas/Roche	7	100.0	0.0	0.0	27.0	2.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol PTS



QUALAB tolerance : 10 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	18	83.3	11.1	5.6	5.01	6.8	e*

Cholesterol HDL PTS



QUALAB tolerance : 21 %

Cholesterol HDL PTS (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	18	88.9	0.0	11.1	2.06	9.5	e

Triglycerides



QUALAB tolerance : 18 %
(< 1.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	CardioChek	18	88.8	5.6	5.6	0.89	10.1	e*

C-Peptid



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	6	100.0	0.0	0.0	5.14	4.3	e
2	Other methods	5	100.0	0.0	0.0	3.83	6.6	e

ACTH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	21.60	12.2	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Procalcitonin



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Architect	6	100.0	0.0	0.0	17.53	6.1	e
2	Cobas	14	92.9	0.0	7.1	14.36	5.5	e
3	VIDAS	12	100.0	0.0	0.0	11.35	9.3	e
4	Other methods	5	100.0	0.0	0.0	11.26	7.5	e*
5	Liaison	5	80.0	0.0	20.0	21.00	4.1	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

EPO



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Immulite	4	100.0	0.0	0.0	40.4	11.6	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Parathyroid hormone



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas PTH STAT	9	100.0	0.0	0.0	9.8	8.5	e
2	Cobas	12	91.7	8.3	0.0	9.1	14.1	e*
3	IDS	4	100.0	0.0	0.0	13.6	8.0	e*
4	Architect	4	100.0	0.0	0.0	19.7	6.8	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality



QUALAB tolerance : 6 %

Osmolality (mosm/kg)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	21	90.5	0.0	9.5	298	1.2	e

Potassium-K22



QUALAB tolerance : 6 %

Potassium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	12	100.0	0.0	0.0	3.8	1.2	e

Sodium-K22



QUALAB tolerance : 6 %

Sodium-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	ISE	12	100.0	0.0	0.0	133	1.3	e

Glucose-K22



QUALAB tolerance : 9 %

Glucose-K22 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	6.0	2.6	e

Urea-K22



QUALAB tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	12	100.0	0.0	0.0	4.5	4.5	e

Osmotic Gap



MQ tolerance : 20 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Formel 1 (2Na+K+Glu+	12	83.4	8.3	8.3	18.5	31.3	a

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Digoxin



QUALAB tolerance : 24 %

Digoxin (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	9	100.0	0.0	0.0	3.64	4.6	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Phenytoin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	82	3.5	e

Phenobarbital



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	207	5.8	e

Paracetamol



MQ tolerance : 25 %

Paracetamol (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	688.0	15.3	d

Vancomycin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Architect	4	100.0	0.0	0.0	22	10.4	e*

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Valproat



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	8	100.0	0.0	0.0	712.0	5.5	e

Carbamazepin



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	47.5	7.9	e*

Cystatin C



MQ tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	92.9	7.1	0.0	3.72	12.4	e*

Ethanol



QUALAB tolerance : 18 %

Ethanol (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	28	100.0	0.0	0.0	35.3	4.7	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Ammonia



MQ tolerance : 25 %

Ammonia (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Architect	4	100.0	0.0	0.0	168.1	8.4	e*
2	all Participants	4	100.0	0.0	0.0	205.2	1.7	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Calprotectin



MQ tolerance : 40 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Bühlmann ELISA	4	75.0	25.0	0.0	183	33.4	e*
2	Bühlmann fCALturbo	15	86.7	0.0	13.3	171	18.1	e
3	Bühlmann Quantum Blu	4	50.0	25.0	25.0	167	41.9	e*
4	Liaison	19	94.7	0.0	5.3	86	10.1	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Cholesterol total Af/b101



QUALAB tolerance : 10 %

Cholesterol total Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	268	97.8	0.7	1.5	4.89	2.8	e
2	Afinion	374	97.3	1.6	1.1	4.82	3.6	e

Cholesterol HDL Af/b101



QUALAB tolerance : 21 %

Cholesterol HDL Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	266	92.5	0.0	7.5	0.91	3.8	e
2	Afinion	373	89.0	0.5	10.5	0.89	4.4	e

Tryglycerides Af/b101



QUALAB tolerance : 18 %

Tryglycerides Af/b101 (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas b101	266	98.5	0.4	1.1	1.66	2.9	e
2	Afinion	376	99.2	0.8	0.0	1.63	4.9	e

Troponin I S



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS (Gen. 1)	15	60.0	13.3	26.7	5252.63	16.2	e*
2	AFIAS	191	65.9	19.4	14.7	696.00	18.9	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

D-dimer qn S



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	210	83.8	1.4	14.8	0.41	8.6	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

NT-proBNP S



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	AFIAS	160	98.1	0.0	1.9	3828.9	10.1	e

Homocystein



MQ tolerance : 30 %

Homocystein (µmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Beckman	4	100.0	0.0	0.0	11.2	4.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Lipase



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche	7	100.0	0.0	0.0	35.0	2.3	e
2	Alinity	5	100.0	0.0	0.0	32.0	10.5	e*
3	Cobas Integra 800/40	5	100.0	0.0	0.0	35.0	1.3	e
4	Architect	7	100.0	0.0	0.0	33.0	4.1	e
5	Beckman	5	100.0	0.0	0.0	33.0	2.9	e
6	Cobas	11	100.0	0.0	0.0	34.7	2.6	e
7	Fuji Dri-Chem	175	96.0	0.0	4.0	44.9	5.7	e

7 additional results were submitted but not published because the method groups were too small. (< results per group)

Bicarbonat



MQ tolerance : 15 %

Bicarbonat (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	4	100.0	0.0	0.0	17.0	2.9	e
2	Piccolo	4	100.0	0.0	0.0	18.5	3.1	e
3	Other methods	5	80.0	20.0	0.0	17.0	10.8	e*

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Glucose CSF



QUALAB tolerance : 9 %
(< 3.30: +/- 0.30 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	8	100.0	0.0	0.0	1.60	2.2	e
2	Other methods	11	100.0	0.0	0.0	1.60	6.0	e*

Lactate CSF



QUALAB tolerance : 18 %

Lactate CSF (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	3.80	5.7	e*
2	Other methods	8	87.5	0.0	12.5	3.77	3.0	e

Protein CSF



QUALAB tolerance : 15 %

Protein CSF (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	7	100.0	0.0	0.0	0.89	2.5	e
2	Other methods	9	100.0	0.0	0.0	0.91	3.2	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Albumine CSF



MQ tolerance : 20 %

Albumine CSF (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	5	100.0	0.0	0.0	348.00	4.0	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Tacrolimus



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	9	100.0	0.0	0.0	12.5	7.0	e

Totalprotein E



MQ tolerance : 12 %

Totalprotein E (g/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	18	100.0	0.0	0.0	75.9	3.6	e

Albumin E



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	24	91.7	8.3	0.0	63.9	6.5	e

alpha-1-Globuline



MQ tolerance : 30 %

alpha-1-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	8	100.0	0.0	0.0	2.0	10.4	e*
2	capillary electropho	15	93.3	0.0	6.7	3.3	6.0	e

alpha-2-Globuline



MQ tolerance : 30 %

alpha-2-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	23	95.7	4.3	0.0	9.3	15.0	a

beta-Globuline



MQ tolerance : 30 %

beta-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	13	100.0	0.0	0.0	10.1	11.2	e

Beta-1-Globulin



MQ tolerance : 30 %

Beta-1-Globulin (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	13	100.0	0.0	0.0	7.0	4.5	e

Beta-2-Globulin



MQ tolerance : 30 %

Beta-2-Globulin (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	8	100.0	0.0	0.0	3.8	10.0	e

gamma-Globuline



MQ tolerance : 30 %

gamma-Globuline (%)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	16	100.0	0.0	0.0	15.5	4.3	e

Gamma-Globuline+P



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Electrophoresis	8	100.0	0.0	0.0	12.5	4.2	e

Immunfixation



QUALAB tolerance : 1 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Interpretation	21	100.0	0.0	0.0	4	0.0	e

Folate in Erythrocytes



MQ tolerance : 40 %

Folate in Erythrocytes (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Alinity	4	100.0	0.0	0.0	545	11.2	e*
2	Architect	6	100.0	0.0	0.0	481	25.4	e*
3	Roche, Cobas	15	93.3	0.0	6.7	2034	15.6	e
4	ADVIA Centaur XP/CP	5	100.0	0.0	0.0	778	17.1	e*

Gallensäure



MQ tolerance : 30 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Other methods	10	100.0	0.0	0.0	8.1	5.4	e
2	all Participants	17	100.0	0.0	0.0	6.7	8.8	e

BNP



QUALAB tolerance : 27 %
(< 75.0: +/- 20.0 ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	15	93.3	0.0	6.7	11.2	28.5	e*

Troponin Triage



QUALAB tolerance : 24 %

Troponin Triage (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage high sensitiv	37	91.9	5.4	2.7	360.67	14.4	e

4 additional results were submitted but not published because the method groups were too small. (< results per group)

NT-pro BNP



QUALAB tolerance : 27 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	23	87.0	4.3	8.7	266	13.8	e

D-dimer Triage



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Triage	45	84.4	6.7	8.9	887.88	10.8	e

Vitamin D 25 (OH)



QUALAB tolerance : 27 %

Vitamin D 25 (OH) (nmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	LCMS	5	100.0	0.0	0.0	68.6	6.5	e
2	Cobas	14	100.0	0.0	0.0	59.2	6.9	e
3	VIDAS	6	100.0	0.0	0.0	59.9	10.1	e*
4	Other methods	15	100.0	0.0	0.0	55.8	14.9	e*
5	Architect	9	100.0	0.0	0.0	64.0	3.4	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

AMH



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	14	100.0	0.0	0.0	17.2	7.0	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Inhibin B



MQ tolerance : 25 %

Inhibin B (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	100.0	0.0	0.0	9.3	19.6	a

Calcitonin



MQ tolerance : 25 %

Calcitonin (pmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Liaison	4	100.0	0.0	0.0	6.6	4.2	e
2	Other methods	4	100.0	0.0	0.0	25.1	3.9	e

Anti Thyreoglobulin



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	100.0	0.0	0.0	13	14.1	a

11 additional results were submitted but not published because the method groups were too small. (< results per group)

Anti TPO



QUALAB tolerance : 25 %
(< 10: +/- 3 IU/ml)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas	9	88.9	0.0	11.1	9	10.9	e*
2	Architect	4	100.0	0.0	0.0	2	78.1	e*

6 additional results were submitted but not published because the method groups were too small. (< results per group)

TRAK



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	6	83.3	16.7	0.0	0.85	14.6	e*

8 additional results were submitted but not published because the method groups were too small. (< results per group)

Creatinine WB



QUALAB tolerance : 18 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Statsensor i / Nova	50	78.0	14.0	8.0	112	12.1	e

IL6



MQ tolerance : 30 %

IL6 (ng/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Roche, Cobas	5	100.0	0.0	0.0	41.8	2.8	e

Calcium-Urine



MQ tolerance : 9 %
(< 2.00: +/- 0.18 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	23	100.0	0.0	0.0	1.78	3.4	e

Chloride-Urine



MQ tolerance : 12 %

Chloride-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	9	100.0	0.0	0.0	100	4.4	e*
2	Roche, Cobas	8	100.0	0.0	0.0	93	3.9	e

3 additional results were submitted but not published because the method groups were too small. (< results per group)

Glucose-Urine



QUALAB tolerance : 9 %
(< 3.3: +/- 0.3 mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	19	100.0	0.0	0.0	1.7	4.1	e

Magnesium-Urine



MQ tolerance : 12 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	13	100.0	0.0	0.0	1.67	4.9	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Osmolality-Urine



MQ tolerance : 10 %

Osmolality-Urine (mosm/kg)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cryoskopy	18	100.0	0.0	0.0	437	1.2	e

Phosphate-Urine



MQ tolerance : 15 %

Phosphate-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	20	100.0	0.0	0.0	8.3	4.4	e

Potassium-Urine



MQ tolerance : 15 %

Potassium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	29	100.0	0.0	0.0	31	1.7	e

Protein-Urine



QUALAB tolerance : 20 %

Protein-Urine (mg/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Cobas/Roche	14	100.0	0.0	0.0	190.6	5.2	e
2	Standard chemistry	15	86.7	0.0	13.3	233.7	5.5	e

5 additional results were submitted but not published because the method groups were too small. (< results per group)

Sodium-Urine



MQ tolerance : 15 %

Sodium-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	30	100.0	0.0	0.0	79	3.3	e

Urea-Urine



MQ tolerance : 15 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	25	100.0	0.0	0.0	148	5.4	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)

Uric Acid-Urine



MQ tolerance : 15 %

Uric Acid-Urine (mmol/l)

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Standard chemistry	16	100.0	0.0	0.0	0.56	5.2	e

2 additional results were submitted but not published because the method groups were too small. (< results per group)

Specific Gravity-Urine



MQ tolerance : 5 %

Specific Gravity-Urine ()

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Refractometer	6	100.0	0.0	0.0	1.013	0.4	e

Ethylglucuronid



MQ tolerance : 25 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	all Participants	4	75.0	0.0	25.0	1.89	8.1	e*

Creatinine U



QUALAB tolerance : 24 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	Aution	4	50.0	0.0	50.0	40.0	0.0	a
2	AFIAS	13	100.0	0.0	0.0	49.0	15.4	a
3	Afinion	441	97.0	0.7	2.3	38.5	8.9	a
4	Sysmex U	19	73.7	0.0	26.3	40.0	17.0	a
5	Other methods	5	60.0	0.0	40.0	40.0	0.0	a
6	Turbidimetry	32	100.0	0.0	0.0	44.3	10.4	a
7	DCA2000/Vantage	155	94.8	2.6	2.6	42.7	10.2	a
8	Siemens Clinitek	18	88.9	0.0	11.1	40.0	0.0	a

Creatinin Urin



QUALAB tolerance : 21 %

No.	Methode	Total	% OK	% insuff.	% outlier	Target	CV%	Type
1	DCA2000/Vantage	153	94.1	2.0	3.9	5.0	6.3	e
2	Siemens Clinitek	7	28.6	0.0	71.4	4.4	0.3	a
3	Afinion	439	97.0	0.0	3.0	4.2	5.1	e
4	Standard chemistry	44	100.0	0.0	0.0	4.7	4.6	e
5	Sysmex U	15	66.7	0.0	33.3	4.4	0.1	a
6	Aution	5	40.0	0.0	60.0	4.4	0.0	a
7	Siemens Clinitek	11	27.3	0.0	72.7	4.4	0.3	a
8	Other methods	5	60.0	0.0	40.0	4.4	0.3	e

One result was submitted but not pubished because the method group was too small. (< 4 results per group)